Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.58
MRK's Cash to Debt is ranked higher than
56% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. MRK: 0.58 )
MRK' s 10-Year Cash to Debt Range
Min: 0.32   Max: 2.45
Current: 0.58

0.32
2.45
Equity to Asset 0.49
MRK's Equity to Asset is ranked higher than
57% of the 728 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. MRK: 0.49 )
MRK' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.53
Current: 0.49

0.34
0.53
Interest Coverage 7.94
MRK's Interest Coverage is ranked higher than
53% of the 454 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.71 vs. MRK: 7.94 )
MRK' s 10-Year Interest Coverage Range
Min: 3.31   Max: 44.62
Current: 7.94

3.31
44.62
F-Score: 6
Z-Score: 3.52
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.44
MRK's Operating margin (%) is ranked higher than
83% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.25 vs. MRK: 14.44 )
MRK' s 10-Year Operating margin (%) Range
Min: 5.15   Max: 37.16
Current: 14.44

5.15
37.16
Net-margin (%) 10.00
MRK's Net-margin (%) is ranked higher than
79% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. MRK: 10.00 )
MRK' s 10-Year Net-margin (%) Range
Min: 1.87   Max: 47.04
Current: 10

1.87
47.04
ROE (%) 8.85
MRK's ROE (%) is ranked higher than
78% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. MRK: 8.85 )
MRK' s 10-Year ROE (%) Range
Min: 1.58   Max: 45.99
Current: 8.85

1.58
45.99
ROA (%) 4.17
MRK's ROA (%) is ranked higher than
73% of the 777 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.87 vs. MRK: 4.17 )
MRK' s 10-Year ROA (%) Range
Min: 0.81   Max: 17.88
Current: 4.17

0.81
17.88
ROC (Joel Greenblatt) (%) 32.08
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.60 vs. MRK: 32.08 )
MRK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 10.5   Max: 65.02
Current: 32.08

10.5
65.02
Revenue Growth (%) -0.10
MRK's Revenue Growth (%) is ranked higher than
61% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. MRK: -0.10 )
MRK' s 10-Year Revenue Growth (%) Range
Min: -24   Max: 23.1
Current: -0.1

-24
23.1
EBITDA Growth (%) 12.60
MRK's EBITDA Growth (%) is ranked higher than
79% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. MRK: 12.60 )
MRK' s 10-Year EBITDA Growth (%) Range
Min: -15.7   Max: 25.8
Current: 12.6

-15.7
25.8
EPS Growth (%) 73.80
MRK's EPS Growth (%) is ranked higher than
97% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. MRK: 73.80 )
MRK' s 10-Year EPS Growth (%) Range
Min: -42.7   Max: 73.8
Current: 73.8

-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MRK Guru Trades in Q3 2013

Signature Select Canadian Fund 291,200 sh (New)
Jim Simons 252,300 sh (New)
Mario Gabelli 195,676 sh (+2.95%)
HOTCHKIS & WILEY 1,059,010 sh (+2.93%)
Jeremy Grantham 13,291,108 sh (+2.65%)
John Buckingham 33,169 sh (+1.75%)
James Barrow 29,641,593 sh (+1.1%)
Irving Kahn 1,228,533 sh (+1.06%)
Manning & Napier Advisors, Inc 422,047 sh (+0.56%)
RS Investment Management 1,601,873 sh (+0.38%)
Leon Cooperman 203,200 sh (unchged)
Mark Hillman 17,807 sh (unchged)
Richard Snow 5,385 sh (unchged)
John Hussman 2,625 sh (unchged)
Louis Moore Bacon 1,228,000 sh (unchged)
Vanguard Health Care Fund 35,919,648 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Tom Russo 5,736 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Charles Brandes 2,702,972 sh (-0.02%)
Jeff Auxier 171,049 sh (-0.06%)
Murray Stahl 48,121 sh (-0.52%)
Dodge & Cox 50,137,596 sh (-1.1%)
Pioneer Investments 2,407,299 sh (-1.34%)
NWQ Managers 125,255 sh (-4.07%)
Ken Fisher 1,099,750 sh (-4.43%)
Bill Frels 113,404 sh (-16.79%)
Steven Cohen 41,275 sh (-28.3%)
Jean-Marie Eveillard 1,134,041 sh (-49.6%)
» More
Q4 2013

MRK Guru Trades in Q4 2013

Louis Moore Bacon 10,000 sh (New)
Ruane Cunniff 4,075 sh (New)
George Soros 150,000 sh (New)
Jim Simons 2,018,534 sh (+700.05%)
Irving Kahn 2,525,376 sh (+105.56%)
Bill Frels 130,654 sh (+15.21%)
Ken Fisher 1,197,965 sh (+8.93%)
John Buckingham 34,302 sh (+3.42%)
RS Investment Management 1,633,719 sh (+1.99%)
Vanguard Health Care Fund 36,561,348 sh (+1.79%)
Richard Snow 5,410 sh (+0.46%)
Prem Watsa 12,000 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Mario Gabelli 195,671 sh (unchged)
George Soros 129,300 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Bill Nygren 1,587,000 sh (unchged)
Mark Hillman 17,807 sh (unchged)
John Hussman 2,625 sh (unchged)
Louis Moore Bacon 500,000 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Murray Stahl 48,071 sh (-0.1%)
Jeff Auxier 170,849 sh (-0.12%)
James Barrow 29,423,811 sh (-0.73%)
NWQ Managers 123,726 sh (-1.22%)
Dodge & Cox 48,798,496 sh (-2.67%)
Manning & Napier Advisors, Inc 409,182 sh (-3.05%)
HOTCHKIS & WILEY 1,018,710 sh (-3.81%)
Pioneer Investments 2,211,185 sh (-8.15%)
Charles Brandes 2,476,201 sh (-8.39%)
Tom Russo 4,536 sh (-20.92%)
Jeremy Grantham 9,665,336 sh (-27.28%)
Jean-Marie Eveillard 14,050 sh (-98.76%)
» More
Q1 2014

MRK Guru Trades in Q1 2014

David Dreman 4,431 sh (New)
Joel Greenblatt 3,567 sh (New)
Steven Cohen 705,823 sh (New)
Paul Tudor Jones 5,035 sh (New)
Jean-Marie Eveillard 2,236,839 sh (+15820.6%)
Ruane Cunniff 4,409 sh (+8.2%)
Pioneer Investments 2,345,288 sh (+6.06%)
Signature Select Canadian Fund 299,500 sh (+2.85%)
RS Investment Management 1,668,798 sh (+2.15%)
Prem Watsa 12,000 sh (unchged)
Richard Snow 5,410 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
Tom Russo 4,536 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Bill Nygren Sold Out
George Soros Sold Out
John Buckingham Sold Out
John Hussman Sold Out
HOTCHKIS & WILEY Sold Out
Louis Moore Bacon Sold Out
Murray Stahl 48,051 sh (-0.04%)
Charles Brandes 2,451,125 sh (-1.01%)
Vanguard Health Care Fund 35,616,848 sh (-2.58%)
Jeff Auxier 164,199 sh (-3.89%)
Bill Frels 114,212 sh (-12.58%)
Manning & Napier Advisors, Inc 353,494 sh (-13.61%)
Mario Gabelli 160,316 sh (-18.07%)
Dodge & Cox 39,959,196 sh (-18.11%)
James Barrow 22,739,030 sh (-22.72%)
NWQ Managers 93,255 sh (-24.63%)
Ken Fisher 725,058 sh (-39.48%)
Irving Kahn 1,128,415 sh (-55.32%)
Jeremy Grantham 2,519,078 sh (-73.94%)
Jim Simons 196,200 sh (-90.28%)
» More
Q2 2014

MRK Guru Trades in Q2 2014

George Soros 86,800 sh (New)
Joel Greenblatt 126,844 sh (+3456.04%)
Ken Fisher 6,464,243 sh (+791.55%)
Jim Simons 795,534 sh (+305.47%)
Paul Tudor Jones 13,266 sh (+163.48%)
Pioneer Investments 4,256,501 sh (+81.49%)
Manning & Napier Advisors, Inc 380,192 sh (+7.55%)
Ruane Cunniff 4,609 sh (+4.54%)
Murray Stahl 48,271 sh (+0.46%)
James Barrow 22,793,207 sh (+0.24%)
Steven Cohen 17,200 sh (unchged)
Mario Gabelli 160,316 sh (unchged)
Richard Snow 5,410 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Robert Bruce 261,500 sh (unchged)
Brian Rogers 6,625,700 sh (unchged)
David Dreman Sold Out
Charles Brandes 2,434,531 sh (-0.68%)
Irving Kahn 1,120,074 sh (-0.74%)
Tom Russo 4,386 sh (-3.31%)
Vanguard Health Care Fund 33,889,948 sh (-4.85%)
Bill Frels 107,546 sh (-5.84%)
Jeff Auxier 149,734 sh (-8.81%)
NWQ Managers 84,311 sh (-9.59%)
Dodge & Cox 35,960,137 sh (-10.01%)
Jean-Marie Eveillard 1,755,082 sh (-21.54%)
RS Investment Management 861,075 sh (-48.4%)
Jeremy Grantham 340,971 sh (-86.46%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Reduce -4.85%0.28%$54.83 - $59.62 $ 60.115%33889948
Dodge & Cox 2014-06-30 Reduce -10.01%0.23%$54.83 - $59.62 $ 60.115%35960137
Joel Greenblatt 2014-06-30 Add 3456.04%0.09%$54.83 - $59.62 $ 60.115%126844
Jean-Marie Eveillard 2014-06-30 Reduce -21.54%0.07%$54.83 - $59.62 $ 60.115%1755082
George Soros 2014-06-30 New Buy0.04%$54.83 - $59.62 $ 60.115%86800
David Dreman 2014-06-30 Sold Out 0.02%$54.83 - $59.62 $ 60.115%0
James Barrow 2014-03-31 Reduce -22.72%0.48%$49.49 - $57.47 $ 60.1111%22739030
Dodge & Cox 2014-03-31 Reduce -18.11%0.45%$49.49 - $57.47 $ 60.1111%39959196
Jean-Marie Eveillard 2014-03-31 Add 15820.6%0.34%$49.49 - $57.47 $ 60.1111%2236839
Vanguard Health Care Fund 2014-03-31 Reduce -2.58%0.15%$49.49 - $57.47 $ 60.1111%35616848
George Soros 2014-03-31 Sold Out 0.06%$49.49 - $57.47 $ 60.1111%0
David Dreman 2014-03-31 New Buy0.02%$49.49 - $57.47 $ 60.1111%4431
John Hussman 2014-03-31 Sold Out 0.01%$49.49 - $57.47 $ 60.1111%0
Joel Greenblatt 2014-03-31 New Buy$49.49 - $57.47 $ 60.1111%3567
Jean-Marie Eveillard 2013-12-31 Reduce -98.76%0.16%$45.09 - $50.18 $ 60.1126%14050
Leon Cooperman 2013-12-31 Sold Out 0.15%$45.09 - $50.18 $ 60.1126%0
Charles Brandes 2013-12-31 Reduce -8.39%0.14%$45.09 - $50.18 $ 60.1126%2476201
George Soros 2013-12-31 New Buy0.06%$45.09 - $50.18 $ 60.1126%150000
Ruane Cunniff 2013-12-31 New Buy$45.09 - $50.18 $ 60.1126%4075
Jean-Marie Eveillard 2013-09-30 Reduce -49.6%0.16%$46.55 - $48.58 $ 60.1126%1134041
George Soros 2013-09-30 Sold Out 0.13%$46.55 - $48.58 $ 60.1126%0
Joel Greenblatt 2013-09-30 Sold Out 0.05%$46.55 - $48.58 $ 60.1126%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Merck & Co Inc

Bill Nygren Comments on Merck - Apr 10, 2014

We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value.

From Bill Nygren (Trades, Portfolio)'s Oakmark Fund first quarter 2014 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Merck & Co Inc

Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...
Bill Nygren Comments on Merck
We eliminated our position in Merck (MRK) as the shares appreciated to our estimate of fair value. Read more...
Vanguard Health Care Fund’s Top Five
Over the duration of the fourth quarter the Vanguard Health Care Fund purchased added four new stocks to its holdings. The fund now holds on to 93 stocks valued at $32.35 billion. The following companies are Vanguard's top five portfolio holdings. Read more...
Merck and Seadrill Top GuruFocus Dividend Growers of the Week
During the past week, GuruFocus recognized two companies as dividend growers. In order to be qualified for this list, the company had to: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.70
MRK's P/E(ttm) is ranked higher than
77% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.30 vs. MRK: 31.70 )
MRK' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 139.89
Current: 31.7

6.67
139.89
P/B 3.63
MRK's P/B is ranked higher than
61% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. MRK: 3.63 )
MRK' s 10-Year P/B Range
Min: 1.72   Max: 7.78
Current: 3.63

1.72
7.78
P/S 4.09
MRK's P/S is ranked higher than
58% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. MRK: 4.09 )
MRK' s 10-Year P/S Range
Min: 1.98   Max: 5.48
Current: 4.09

1.98
5.48
PFCF 17.17
MRK's PFCF is ranked higher than
93% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 17.17 )
MRK' s 10-Year PFCF Range
Min: 7.8   Max: 86.81
Current: 17.17

7.8
86.81
EV-to-EBIT 29.72
MRK's EV-to-EBIT is ranked higher than
75% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.72 vs. MRK: 29.72 )
MRK' s 10-Year EV-to-EBIT Range
Min: 8.5   Max: 104
Current: 29.72

8.5
104
Shiller P/E 24.57
MRK's Shiller P/E is ranked higher than
81% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 150.63 vs. MRK: 24.57 )
MRK' s 10-Year Shiller P/E Range
Min: 8.26   Max: 24.53
Current: 24.57

8.26
24.53
Current Ratio 1.87
MRK's Current Ratio is ranked higher than
60% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. MRK: 1.87 )
MRK' s 10-Year Current Ratio Range
Min: 1.07   Max: 3.7
Current: 1.87

1.07
3.7
Quick Ratio 1.53
MRK's Quick Ratio is ranked higher than
65% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. MRK: 1.53 )
MRK' s 10-Year Quick Ratio Range
Min: 0.8   Max: 3.44
Current: 1.53

0.8
3.44

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.91
MRK's Dividend Yield is ranked higher than
84% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. MRK: 2.91 )
MRK' s 10-Year Dividend Yield Range
Min: 2.51   Max: 6.68
Current: 2.91

2.51
6.68
Dividend Payout 0.92
MRK's Dividend Payout is ranked higher than
66% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. MRK: 0.92 )
MRK' s 10-Year Dividend Payout Range
Min: 0.16   Max: 4.22
Current: 0.92

0.16
4.22
Dividend growth (3y) 4.40
MRK's Dividend growth (3y) is ranked higher than
80% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -0.10 vs. MRK: 4.40 )
MRK' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.8
Current: 4.4

0
14.8
Yield on cost (5-Year) 3.48
MRK's Yield on cost (5-Year) is ranked higher than
87% of the 466 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. MRK: 3.48 )
MRK' s 10-Year Yield on cost (5-Year) Range
Min: 3.01   Max: 8.01
Current: 3.48

3.01
8.01
Share Buyback Rate 1.30
MRK's Share Buyback Rate is ranked higher than
89% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.50 vs. MRK: 1.30 )
MRK' s 10-Year Share Buyback Rate Range
Min: 1.8   Max: -13
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.91
MRK's Price/Tangible Book is ranked higher than
59% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.53 vs. MRK: 9.91 )
MRK' s 10-Year Price/Tangible Book Range
Min: 3.19   Max: 3735
Current: 9.91

3.19
3735
Price/DCF (Projected) 1.58
MRK's Price/DCF (Projected) is ranked higher than
89% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.06 vs. MRK: 1.58 )
MRK' s 10-Year Price/DCF (Projected) Range
Min: 0.75   Max: 3.04
Current: 1.58

0.75
3.04
Price/Median PS Value 1.34
MRK's Price/Median PS Value is ranked higher than
66% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. MRK: 1.34 )
MRK' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 2.12
Current: 1.34

0.65
2.12
Price/Graham Number 3.68
MRK's Price/Graham Number is ranked higher than
72% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.75 vs. MRK: 3.68 )
MRK' s 10-Year Price/Graham Number Range
Min: 1.08   Max: 36.98
Current: 3.68

1.08
36.98
Earnings Yield (Greenblatt) 3.40
MRK's Earnings Yield (Greenblatt) is ranked higher than
64% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. MRK: 3.40 )
MRK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 11.8
Current: 3.4

1
11.8
Forward Rate of Return (Yacktman) -2.20
MRK's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 633 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.43 vs. MRK: -2.20 )
MRK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.7   Max: 17.6
Current: -2.2

-2.7
17.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:0QAH.country, MRK.France, 6MK.Germany
Merck & Co Inc is a New Jersey corporation. The Company is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company's operations are mainly managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products, which are sold through wholesale and retail drug, food chain and mass merchandiser outlets, as well as club stores and specialty channels. The Company's competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, and generic drug and consumer health care manufacturers. The Company's activities, including research, preclinical testing, clinical trials and manufacturing and marketing its products, are subject to regulation by numerous federal, state and local governmental authorities in the United States, including the FDA, and by foreign regulatory authorities, including the European Commission.
» More Articles for MRK

Headlines

Articles On GuruFocus.com
I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
Legendary Investor Irving Kahn's Top Five Stocks Aug 08 2014 
UnitedHealth Group Up on Weak Day for the Dow Jul 17 2014 
U.S. Markets Regain Losses from Last Week Jul 14 2014 
Abner Herrman Is Increasing Position in the Pharmaceutical Sector Jul 11 2014 
U.S. Equity Markets Continue to Hit New Highs Jun 15 2014 
Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
Wrong Marketing Lesson by Big Pharma May 03 2014 


More From Other Websites
Pfizer and Merck Collaborate to Develop Lung Cancer Therapy Aug 27 2014
[video] Options Insight: Unusual Activities on The Dow Aug 27 2014
Will This Coverage Initiation Affect Merck (MRK) Stock Today? Aug 27 2014
UPDATE: Deutsche Bank Initiates Coverage On Merck Aug 27 2014
Merck, Pfizer combining drugs Aug 26 2014
Your first trade for Wednesday Aug 26 2014
Merck Is at the $60 Rubicon; Can It Cross This Time? Aug 26 2014
The 4 Stocks That Pushed the DJIA and S&P 500 to New Highs Aug 26 2014
[video] Why & what of the stock market Aug 26 2014
Why Merck (MRK) Stock Is Gaining Today Aug 26 2014
Dow Today: Merck (MRK) Higher Aug 26 2014
[video] FMHR Final Trade: RIG, MRK & more Aug 26 2014
Merck, Pfizer Combining Drugs In Lung Cancer Study Aug 26 2014
Pfizer to test Xalkori lung cancer drug with Merck immunotherapy Aug 26 2014
[$$] Pfizer, Merck Team Up on Cancer Study Aug 26 2014
Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen Aug 26 2014
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan and Announces Opening... Aug 26 2014
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan and Announces Opening... Aug 25 2014
The 4 Stocks That Helped Lift the S&P Above 2,000 Aug 25 2014
Business events scheduled for Tuesday Aug 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK